Caplin Point Laboratories

    CAPLIPOINT
    Pharma
    ₹2,085.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹15,851 Cr

    P/E
    23.07
    Day range
    ₹2,072.00 – ₹2,239.60
    52-week range
    ₹1,500.30 – ₹2,990.00
    Volume
    7.10 L
    Open
    ₹2,231.00
    Prev close
    ₹2,247.10

    Latest results · Q2 FY27(consolidated)Revenue ₹630 Cr+17.9%Profit ₹182 Cr+13.8%Margin 29.0%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 59 / 100

    Factor percentiles

    Value57
    Quality75
    Momentum47
    Low volatility57

    Derived metrics

    Earn. yield
    4.3%
    Graham no.
    ₹954.84
    vs Graham
    -54.2%
    ROE ÷ P/B
    4.6%
    12-1 mom.
    +18.4%
    Return / vol
    0.21
    Magic Formula
    #95
    Piotroski
    3/6
    FCF yield
    1.7%
    PEG
    1.21

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Caplin Point LaboratoriesCAPLIPOINT₹15,851 Cr23.074.6621.7%24.0%35.0%0.00+18.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 10h ago

    Headlines about Caplin Point Laboratories from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    23.0
    Price / Book
    4.06
    ROE (FY26)
    21.7%
    ROCE (latest year)
    24%
    Dividend yield
    0.38%

    Moving averages (NSE)

    20-day
    ₹2,339.08
    Price below
    50-day
    ₹2,516.98
    Price below
    200-day
    ₹2,196.66
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.2%
    Profit 3Y CAGR
    +19.9%
    Revenue YoY (Sep 2026)
    +18.0%
    Profit YoY (Sep 2026)
    +13.7%
    Operating margin
    35.0%
    Net margin
    28.9%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr800 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-1K Cr-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%20%40%60%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr4K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹2₹4₹6₹8

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales436453459483493502510534543600610630
    Expenses293308307318331334332345353396397407
    Operating Profit142145152165162168178189190204213223
    OPM %33%32%33%34%33%33%35%35%35%34%35%35%
    Other Income171719213126233034283433
    Interest000000000000
    Depreciation141616171617161819192223
    Profit before tax145146154168177177184201204213225233
    Tax %18%17%19%22%21%18%18%20%19%19%20%22%
    Net Profit120121125131140145151160166173179182
    EPS in Rs₹15.43₹16.01₹16.31₹17.21₹18.28₹18.76₹20.10₹20.32₹21.56₹22.38₹23.27₹23.43

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days138

    +42 days since Mar 2021

    Inventory Days181

    +42 days since Mar 2021

    Days Payable125

    +57 days since Mar 2021

    Cash Conversion Cycle194

    +28 days since Mar 2021

    Working Capital Days199

    +54 days since Mar 2021

    Strengths, risks & growth

    Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]

    Strengths

    • Company has reduced debt.
    • Company is almost debt free.
    • Company has delivered good profit growth of 21.4% CAGR over last 5 years
    • Company's median sales growth is 19.9% of last 10 years

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    +25%
    5 Years
    +16%
    3 Years
    +14%
    TTM
    +17%

    Compounded Profit Growth

    10 Years
    +30%
    5 Years
    +21%
    3 Years
    +19%
    TTM
    +17%

    Stock Price CAGR

    10 Years
    +20%
    5 Years
    +20%
    3 Years
    +18%
    1 Year
    +8%

    Return on Equity

    10 Years
    +25%
    5 Years
    +23%
    3 Years
    +22%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter70.57%70.57%70.57%70.57%0.00 pp
    FII6.58%6.15%5.76%5.72%-0.04 pp
    DII2.05%2.14%2.49%2.20%-0.29 pp
    Public20.81%21.14%21.19%21.52%+0.33 pp

    Filed with NSE for Sept 2026: promoters 70.57%, public 29.43%

    Analysts & fund holdings

    100%
    100% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E23.1 vs 45.2
    Sector P/B6.05
    Beta0.76

    Who holds the shares, quarter by quarter

    Mutual funds 1.64% (-0.39 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters70.6%
    • Foreign institutions5.7%
    • Mutual funds1.6%
    • Insurance0.1%
    • Other domestic institutions0.5%
    • Retail13.8%
    • Others7.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    UTI Small Cap Fund0.45%1.61%-0.12 pp
    UTI Large & Mid Cap Fund0.32%0.93%-0.24 pp
    UTI Aggressive Hybrid Fund0.25%0.70%-0.27 pp
    UTI Healthcare Fund0.21%2.68%-1.27 pp
    Nippon India Nifty Smallcap 250 Index Fund0.04%0.22%-0.01 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    35.2%
    Downside volatility
    34.0%
    Worst 5% of days
    3.5%
    Average of that tail
    5.1%
    Max drawdown (1Y)
    35.8%
    Below its peak
    27.3%

    Against the market

    Beta vs Nifty 50
    0.81
    Correlation
    0.31
    Relative strength (3M)
    -21.2%
    ATR (14)
    4.9%

    Return

    Return 1M
    -9.4%
    Return 3M
    -17.3%
    Return 6M
    +5.0%
    Return 1Y
    +7.3%
    vs 200-day average
    -5.1%

    Momentum

    RSI (14) · oversold
    29.8
    MACD histogram
    -13.42
    Stochastic %K
    2.5
    ADX (14)
    19.9
    +DI / −DI
    18.0 / 37.9
    Money flow index
    20.6

    Participation

    Delivery (20d avg)
    44.7%
    vs its 60-day baseline
    +4.3 pts
    Volume vs 20-day
    +6.1σ
    Close vs day's VWAP
    -0.8%
    52-week position
    43 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹275 Cr
    FCF yield
    1.7%
    Cash conversion
    0.81
    Accruals ratio
    0.031
    Net debt
    -₹601 Cr
    Net debt / equity
    -0.17
    EV / sales
    6.40
    PEG
    1.21
    Capex intensity
    11.3%
    Revenue CAGR
    19.4%
    Profit CAGR
    19.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      18 Sept 2026
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      29 May 2026
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      12 Sept 2025
      ex-date
    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      30 May 2025
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      23 Sept 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Sept 2024
      ex-date
    • dividend
      ₹2.50

      Interim Dividend - Rs 2.50 Per Share

      31 May 2024
      ex-date
    • dividend
      ₹2.50

      Annual General Meeting/Dividend - Rs 2.50 Per Share

      14 Sept 2023
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      9 Jun 2023
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      21 Sept 2022
      ex-date
    • dividend
      ₹2.00

      Interim Dividend - Rs 2 Per Share

      23 May 2022
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting/Dividend - Rs 1.50 Per Share

      20 Sept 2021
      ex-date
    • dividend
      ₹1.50

      Interim Dividend - Rs 1.50 Per Share

      18 May 2021
      ex-date
    • dividend
      ₹0.40

      Annual General Meeting/Dividend - Rs 0.40 Per Share

      21 Sept 2020
      ex-date
    • dividend
      ₹2.10

      Interim Dividend - Rs 2.10 Per Share

      12 Mar 2020
      ex-date
    • dividend
      ₹2.20

      Annual General Meeting/Dividend - Rs 2.20 Per Share

      4 Sept 2019
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend- Rs 2 Per Share

      18 Sept 2018
      ex-date
    • dividend
      ₹1.50

      Annual General Meeting/Dividend - Rs 1.50 Per Share

      7 Sept 2017
      ex-date
    • other
      Not available — not reported in this filing

      Fv Splt Frm Rs 10 To Rs 2

      19 Oct 2016
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      1 Sept 2016
      ex-date

    Company announcements

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter and half year ended September 30, 2026.

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window for the quarter and half year ended September 30, 2026 commencing from October 01, 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results and Scrutinizer Report for the 35th Annual General Meeting

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 35th Annual General Meeting of the Company

    Company Update
    Clarification With Respect To Volume Movement

    Clarification with respect to Volume Movement

    Company UpdatePrice-sensitive
    Clarification sought from Caplin Point Laboratories Ltd

    The Exchange has sought clarification from Caplin Point Laboratories Ltd on September 25, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication for Notice of 35th AGM and E-Voting Information

    Company Update
    Letter To Shareholders

    Letter to Shareholders regarding dispatch of 35th AGM Notice and Annual Report for the Financial year 2025-26

    Others
    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Report for the Financial Year 2025-26

    AGM/EGMPrice-sensitive
    Notice Of The 35Th Annual General Meeting

    Notice of the 35th Annual General Meeting of the Company

    Others
    Reg. 34 (1) Annual Report.

    Annual Report for the Financial Year 2025-26

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication for convening 35th AGM of the Company through Video Conferencing.

    Company Update
    General Updates

    Receipt of Good Manufacturing Practices (GMP) Compliance Certificate by Caplin One Labs Limited (COL), a subsidiary Company, from INVIMA

    Company Update
    General Updates

    Completion of Unannounced USFDA Inspection at the facility of Caplin Steriles Limited (Company's subsidiary)

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript for Earnings call- Q1- FY 2026-27

    Filed with BSE (scrip 524742); the last 45 days. Documents open at bseindia.com.

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Caplin Point Laboratories: common questions

    Answered from the figures on this page.

    Caplin Point Laboratories last traded at ₹2,085.30 (NSE, as of 18 Nov 2026). The last session moved it down 7.20%.

    Caplin Point Laboratories is valued at about ₹15,851 crore (NSE, as of 18 Nov 2026).

    Caplin Point Laboratories trades at a price-to-earnings ratio of 23.07 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Caplin Point Laboratories has traded between ₹1,500.30 and ₹2,990.00 over the past 52 weeks, to 18 Nov 2026. It is currently 39% of the way up that range.

    Caplin Point Laboratories (CAPLIPOINT) is classified under Pharma on this site's screener.